Designer GLP1 poly-agonist peptides in the management of diabesity.

IF 2.7 Q3 ENDOCRINOLOGY & METABOLISM

Expert Review of Endocrinology & Metabolism Pub Date : 2023-05-01 DOI:10.1080/17446651.2023.2204976

Laura Statham, Melina Pelling, Petra Hanson, Ioannis Kyrou, Harpal Randeva, Thomas M Barber

{"title":"Designer GLP1 poly-agonist peptides in the management of diabesity.","authors":"Laura Statham, Melina Pelling, Petra Hanson, Ioannis Kyrou, Harpal Randeva, Thomas M Barber","doi":"10.1080/17446651.2023.2204976","DOIUrl":null,"url":null,"abstract":"Introduction: To date, the 21st Century has witnessed key developments in the management of diabesity (a conflation of obesity and Type 2 Diabetes Mellitus [T2D]), including Glucagon Like Peptide 1 (GLP1) receptor agonist therapies, and recently the 'designer' GLP1 Poly-agonist Peptides (GLP1PPs).Areas covered: A PubMed search of published data on the GLP1PP class of therapies was conducted. The gut-brain axis forms complex multi-directional interlinks that include autonomic nervous signaling, components of the gut microbiota (including metabolic by-products and gram-negative cell wall components [e.g. endotoxinaemia]), and incretin hormones that are secreted from the gut in response to the ingestion of nutrients. The development of dual-incretin agonist therapies includes combinations of the GLP1 peptide with Glucose-dependent Insulinotropic Polypeptide (GIP), Glucagon (Gcg), Cholecystokinin (CCK), Peptide YY (PYY), and Glucagon-Like Peptide 2 (GLP2). Triple incretin agonist therapies are also under development.Expert opinion: At the dawn of a new era in the therapeutic management of diabesity, the designer GLP1PP class holds great promise, with each novel combination building on a preexisting palimpsest of clinical data and insights. Future innovations of the GLP1PP class will likely enable medically induced weight loss and glycemic control in diabesity to rival or even out-perform those resulting from bariatric surgery.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":"18 3","pages":"231-240"},"PeriodicalIF":2.7000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Endocrinology & Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17446651.2023.2204976","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 1

Abstract

Introduction: To date, the 21^st Century has witnessed key developments in the management of diabesity (a conflation of obesity and Type 2 Diabetes Mellitus [T2D]), including Glucagon Like Peptide 1 (GLP1) receptor agonist therapies, and recently the 'designer' GLP1 Poly-agonist Peptides (GLP1PPs).

Areas covered: A PubMed search of published data on the GLP1PP class of therapies was conducted. The gut-brain axis forms complex multi-directional interlinks that include autonomic nervous signaling, components of the gut microbiota (including metabolic by-products and gram-negative cell wall components [e.g. endotoxinaemia]), and incretin hormones that are secreted from the gut in response to the ingestion of nutrients. The development of dual-incretin agonist therapies includes combinations of the GLP1 peptide with Glucose-dependent Insulinotropic Polypeptide (GIP), Glucagon (Gcg), Cholecystokinin (CCK), Peptide YY (PYY), and Glucagon-Like Peptide 2 (GLP2). Triple incretin agonist therapies are also under development.

Expert opinion: At the dawn of a new era in the therapeutic management of diabesity, the designer GLP1PP class holds great promise, with each novel combination building on a preexisting palimpsest of clinical data and insights. Future innovations of the GLP1PP class will likely enable medically induced weight loss and glycemic control in diabesity to rival or even out-perform those resulting from bariatric surgery.

查看原文本刊更多论文

设计GLP1多激动肽在糖尿病管理中的作用。

迄今为止，21世纪见证了糖尿病(肥胖和2型糖尿病[T2D]的合并)管理的关键发展，包括胰高血糖素样肽1 (GLP1)受体激动剂治疗，以及最近的“设计”GLP1多激动剂肽(GLP1PPs)。涵盖领域:PubMed检索了GLP1PP类疗法的已发表数据。肠脑轴形成复杂的多向互联，包括自主神经信号、肠道微生物群成分(包括代谢副产物和革兰氏阴性细胞壁成分[如内毒素血症])，以及肠道因摄入营养物质而分泌的肠促胰岛素激素。双胰促胰岛素激动剂疗法的发展包括GLP1肽与葡萄糖依赖性胰岛素性多肽(GIP)、胰高血糖素(Gcg)、胆囊收缩素(CCK)、肽YY (PYY)和胰高血糖素样肽2 (GLP2)的联合治疗。三联肠促胰岛素激动剂疗法也在开发中。专家意见:在糖尿病治疗管理新时代的黎明，设计师GLP1PP类具有巨大的希望，每一个新的组合都建立在先前存在的临床数据和见解的重写之上。未来GLP1PP类的创新可能会使药物诱导的糖尿病减肥和血糖控制与减肥手术的效果相媲美，甚至超过。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Endocrinology & Metabolism ENDOCRINOLOGY & METABOLISM-

CiteScore

4.80

自引率

0.00%

发文量

期刊介绍： Implicated in a plethora of regulatory dysfunctions involving growth and development, metabolism, electrolyte balances and reproduction, endocrine disruption is one of the highest priority research topics in the world. As a result, we are now in a position to better detect, characterize and overcome the damage mediated by adverse interaction with the endocrine system. Expert Review of Endocrinology and Metabolism (ISSN 1744-6651), provides extensive coverage of state-of-the-art research and clinical advancements in the field of endocrine control and metabolism, with a focus on screening, prevention, diagnostics, existing and novel therapeutics, as well as related molecular genetics, pathophysiology and epidemiology.